Home › Digestive Diseases › New Mexico › Albuquerque
Digestive Diseases clinical trials in Albuquerque, NM
4 studies for Digestive Diseases are looking for participants at sites in and around Albuquerque (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
RecruitingPhase 3
- 89bio Clinical Study Site, Albuquerque
A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
RecruitingPhase 3
- 89bio Clinical Study Site, Albuquerque
Product Surveillance Registry
RecruitingObservational study
- Albuquerque, Albuquerque
Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
RecruitingPhase 3
- University of New Mexico Comprehensive Cancer Center, Albuquerque
About Digestive Diseases
Learn about digestive disorders and how your gastrointestinal (GI) system works. Find out what tests you need in case you sense a problem.
More about Digestive Diseases on MedlinePlus
Digestive Diseases trials in other cities
- New York City, NY7 studies
- Chicago, IL7 studies
- Houston, TX7 studies
- Washington, DC6 studies
- Boston, MA6 studies
- St. Louis, MO5 studies
- San Diego, CA5 studies
- Louisville, KY5 studies
- Durham, NC5 studies
- Nashville, TN5 studies
- Rochester, MN5 studies
- Ann Arbor, MI4 studies
Other studies in Albuquerque
- Breast Cancer17 studies
- Non-Small Cell Lung Cancer17 studies
- Cancer (all types)14 studies
- Lung Cancer14 studies
- Ovarian Cancer13 studies
- Endometrial Cancer12 studies
- Cardiovascular Disease11 studies
- Metastatic Cancer11 studies
- Prostate Cancer10 studies
- Type 2 Diabetes10 studies
- Acute Myeloid Leukemia9 studies
- Melanoma9 studies
From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.